Pharmacokinetics and pharmacodynamics of the new propofol prodrug GPI 15715 in rats
We studied the pharmacokinetics and pharmacodynamics of GPI 15715 (Aquavan injection), a new water-soluble prodrug metabolized to propofol by hydrolysis. Nine adult male Sprague-Dawley rats (398 +/- 31 g) received a bolus dose of 40 mg GPI 15715. The plasma concentrations of GPI 15715 and propofol w...
Saved in:
Published in | European journal of anaesthesiology Vol. 20; no. 3; p. 182 |
---|---|
Main Authors | , , , , , , |
Format | Journal Article |
Language | English |
Published |
England
01.03.2003
|
Subjects | |
Online Access | Get more information |
Cover
Loading…
Abstract | We studied the pharmacokinetics and pharmacodynamics of GPI 15715 (Aquavan injection), a new water-soluble prodrug metabolized to propofol by hydrolysis.
Nine adult male Sprague-Dawley rats (398 +/- 31 g) received a bolus dose of 40 mg GPI 15715. The plasma concentrations of GPI 15715 and propofol were determined from arterial blood samples, and the pharmacokinetics of both compounds were investigated using compartment models whereby the elimination from the central compartment of GPI 15715 was used as drug input for the central compartment of propofol. Pharmacodynamics were assessed using the median frequency of the EEG power spectrum.
A maximum propofol concentration of 7.1 +/- 1.7 microg mL(-1) was reached 3.7 +/- 0.2 min after bolus administration. Pharmacokinetics were best described by two-compartment models. GPI 15715 showed a short half-life (2.9 +/- 0.2 and 23.9 +/- 9.9 min), an elimination rate constant of 0.18 +/- 0.01 min(-1) and a central volume of distribution of 0.25 +/- 0.02 L kg(-1). For propofol, the half-life was 1.9 +/- 0.1 and 45 +/- 7 min, the elimination rate constant was 0.15 +/- 0.02 min(-1) and the central volume of distribution was 2.3 +/- 0.6 L kg(-1). The maximum effect on the electroencephalogram (EEG)--EEG suppression for >4 s--occurred 6.5 +/- 1.2 min after bolus administration and baseline values of the EEG median frequency were regained 30 min later. The EEG effect could be described by a sigmoid Emax model including an effect compartment (E0 = 16.9 +/- 7.9 Hz, EC50 = 2.6 +/- 0.8 microg mL(-1), ke0 = 0.35 +/- 0.04 min(-1)).
Compared with known propofol formulations, propofol from GPI 15715 showed a longer half-life, an increased volume of distribution, a delayed onset, a sustained duration of action and a greater potency with respect to concentration. |
---|---|
AbstractList | We studied the pharmacokinetics and pharmacodynamics of GPI 15715 (Aquavan injection), a new water-soluble prodrug metabolized to propofol by hydrolysis.
Nine adult male Sprague-Dawley rats (398 +/- 31 g) received a bolus dose of 40 mg GPI 15715. The plasma concentrations of GPI 15715 and propofol were determined from arterial blood samples, and the pharmacokinetics of both compounds were investigated using compartment models whereby the elimination from the central compartment of GPI 15715 was used as drug input for the central compartment of propofol. Pharmacodynamics were assessed using the median frequency of the EEG power spectrum.
A maximum propofol concentration of 7.1 +/- 1.7 microg mL(-1) was reached 3.7 +/- 0.2 min after bolus administration. Pharmacokinetics were best described by two-compartment models. GPI 15715 showed a short half-life (2.9 +/- 0.2 and 23.9 +/- 9.9 min), an elimination rate constant of 0.18 +/- 0.01 min(-1) and a central volume of distribution of 0.25 +/- 0.02 L kg(-1). For propofol, the half-life was 1.9 +/- 0.1 and 45 +/- 7 min, the elimination rate constant was 0.15 +/- 0.02 min(-1) and the central volume of distribution was 2.3 +/- 0.6 L kg(-1). The maximum effect on the electroencephalogram (EEG)--EEG suppression for >4 s--occurred 6.5 +/- 1.2 min after bolus administration and baseline values of the EEG median frequency were regained 30 min later. The EEG effect could be described by a sigmoid Emax model including an effect compartment (E0 = 16.9 +/- 7.9 Hz, EC50 = 2.6 +/- 0.8 microg mL(-1), ke0 = 0.35 +/- 0.04 min(-1)).
Compared with known propofol formulations, propofol from GPI 15715 showed a longer half-life, an increased volume of distribution, a delayed onset, a sustained duration of action and a greater potency with respect to concentration. |
Author | Schywalsky, M Ihmsen, H Fechner, J Tzabazis, A Vornov, J Schwilden, H Burak, E |
Author_xml | – sequence: 1 givenname: M surname: Schywalsky fullname: Schywalsky, M organization: University of Erlangen-Nuremberg, Department of Anaesthesiology, Erlangen, Germany – sequence: 2 givenname: H surname: Ihmsen fullname: Ihmsen, H – sequence: 3 givenname: A surname: Tzabazis fullname: Tzabazis, A – sequence: 4 givenname: J surname: Fechner fullname: Fechner, J – sequence: 5 givenname: E surname: Burak fullname: Burak, E – sequence: 6 givenname: J surname: Vornov fullname: Vornov, J – sequence: 7 givenname: H surname: Schwilden fullname: Schwilden, H |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/12650488$$D View this record in MEDLINE/PubMed |
BookMark | eNo1z81KAzEUBeAsKvZHH8CN5AVG83PvJLOUorVQaKF1XTKZxI52kiEzRfr2drCu7uHjcOBOySjE4Ah54OyJM66et0zkyARHJhljUogRmQyUDTYm0677ujheurdkzIcuaD0h283BpMbY-F0H19e2oyZUtL1idQ6mGTB62h8cDe6Htim20cfjEKp0-qSLzZJyVBxpHWgyfXdHbrw5du7-emfk4-11N3_PVuvFcv6yyqwAFBkieoUm11pzRO2s89aBzp33NuccOJSuyBWDkgEo8KKQrACpwXslpQcxI49_u-2pbFy1b1PdmHTe_38nfgFEVk_h |
CitedBy_id | crossref_primary_10_3389_fphar_2022_923353 |
ContentType | Journal Article |
DBID | CGR CUY CVF ECM EIF NPM |
DOI | 10.1017/S0265021503000322 |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) |
DatabaseTitleList | MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | no_fulltext_linktorsrc |
ExternalDocumentID | 12650488 |
Genre | Research Support, Non-U.S. Gov't Retracted Publication Journal Article |
GroupedDBID | --- .GJ .Z2 026 0R~ 1J1 1OC 29G 31~ 36B 4.4 53G 5GY 5RE 5VS 6PF 8-1 AAAAV AAAXR AAGIX AAHPQ AAIQE AAMOA AAQKA AARTV AASCR AAWTL AAXQO AAYEP ABASU ABBUW ABDIG ABITZ ABJNI ABVCZ ABXVJ ABZAD ACCJW ACDDN ACEWG ACGFS ACILI ACLDA ACQPF ACWDW ACWRI ACXJB ACXNZ ACXQS ADFPA ADGGA ADHPY ADNKB AE6 AEETU AENEX AFDTB AFKSM AFUWQ AFZJQ AGINI AHMBA AHOMT AHQNM AHVBC AHXIK AIJEX AINUH AJAOE AJIOK AJNWD AJNYG AJZMW AKULP ALMA_UNASSIGNED_HOLDINGS ALMTX AMJPA AMKUR AMNEI AOHHW ATUCA AWKKM BOYCO BQLVK C45 CAG CGR CHEAL COF CS3 CUY CVF DIWNM DU5 DUNZO E.X EBS ECM EEVPB EIF EJD ERAAH EX3 F5P FCALG FL- GNXGY GQDEL HLJTE HZ~ IHE IKREB IKYAY IN~ IPNFZ JK3 JK8 K8S KD2 L-C L98 LW7 N9A NPM O9- OCUKA ODA OHH OJAPA OPUJH ORVUJ OUVQU OVD OVDNE OVIDH OVLEI OXXIT P2P PQQKQ R58 RCA RIG RLZ ROL S4S TEORI TSPGW V2I W3M WOW WQ3 X3V X3W YFH ZGI ZXP ZZMQN |
ID | FETCH-LOGICAL-c2452-555f75a68881558ecefce486effc611414be96704b04474f293094384ff733f42 |
ISSN | 0265-0215 |
IngestDate | Tue Oct 15 23:26:26 EDT 2024 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 3 |
Language | English |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c2452-555f75a68881558ecefce486effc611414be96704b04474f293094384ff733f42 |
PMID | 12650488 |
ParticipantIDs | pubmed_primary_12650488 |
PublicationCentury | 2000 |
PublicationDate | 2003-March |
PublicationDateYYYYMMDD | 2003-03-01 |
PublicationDate_xml | – month: 03 year: 2003 text: 2003-March |
PublicationDecade | 2000 |
PublicationPlace | England |
PublicationPlace_xml | – name: England |
PublicationTitle | European journal of anaesthesiology |
PublicationTitleAlternate | Eur J Anaesthesiol |
PublicationYear | 2003 |
References | 20220359 - Eur J Anaesthesiol. 2010 Apr;27(4):402 |
References_xml | |
SSID | ssj0005101 |
Score | 1.8770738 |
SecondaryResourceType | retracted_publication |
Snippet | We studied the pharmacokinetics and pharmacodynamics of GPI 15715 (Aquavan injection), a new water-soluble prodrug metabolized to propofol by hydrolysis.
Nine... |
SourceID | pubmed |
SourceType | Index Database |
StartPage | 182 |
SubjectTerms | Anesthetics, Intravenous - pharmacokinetics Anesthetics, Intravenous - pharmacology Animals Biotransformation Blood Pressure - drug effects Delayed-Action Preparations Electroencephalography - drug effects Half-Life Male Models, Biological Prodrugs - pharmacokinetics Prodrugs - pharmacology Propofol - analogs & derivatives Propofol - pharmacokinetics Propofol - pharmacology Rats Rats, Sprague-Dawley |
Title | Pharmacokinetics and pharmacodynamics of the new propofol prodrug GPI 15715 in rats |
URI | https://www.ncbi.nlm.nih.gov/pubmed/12650488 |
Volume | 20 |
hasFullText | |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3dT8IwEG9QX3wxGr-_0gffyMzKuq48GqMCiYQESHgj3dYKUQcR0Mhf73XtBsyPqC_L0i7Htvtxu17vfofQRQwuMYnj0KmGVeFQ6TGnymnswKc_gOVK5Bmy5_smq3Vpo-f3SqXXpayl2TS8jOZf1pX8R6swBnrVVbJ_0GwuFAbgHPQLR9AwHH-l45blnX4EVzGnWx7bwdj0mp9kWQDgP-tsrPFIjZ70Sfwyeyjftepl4gfET-tahKF1-jJSb71WkQj4jgzkZLgSj29Hg_c3eF4Tic2jOfXBs43w5DtSnbkIxdw2QV44olFWedNYiUN4i0Qsa64qTNd6m-LMzLZW3CUMeUuGkpiWQ58MuGV90sK0LDBB8FOVlWtBB-PnVKNEX0VNW8CfZwuc2tnUGloLuLaLTR3jyRKDSNo0O3-ebC88JRov3JfmnLWyCuuS1D_pbKMtu7DAVwYlO6gkk13ULiIEA0JwESF4pDCoFANCcIYQbBGCASE4RQgeJlgjZA91b2861zXHttFwIr2t7vi-rwJfMM45OI9cRlJFknImlYoYLIcJDWWVBS4NXUoDqsAB1OmmnCoVeJ6ilX20nowSeYiw8AiTUjPygwSfuyHxYs6U60r4w3Mhj9CBeQf9seFK6Wdv5_jbmRO0uYDTKdpQAFZ5Bp7eNDxPFfMBm2FNmQ |
link.rule.ids | 786 |
linkProvider | National Library of Medicine |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Pharmacokinetics+and+pharmacodynamics+of+the+new+propofol+prodrug+GPI+15715+in+rats&rft.jtitle=European+journal+of+anaesthesiology&rft.au=Schywalsky%2C+M&rft.au=Ihmsen%2C+H&rft.au=Tzabazis%2C+A&rft.au=Fechner%2C+J&rft.date=2003-03-01&rft.issn=0265-0215&rft.volume=20&rft.issue=3&rft.spage=182&rft_id=info:doi/10.1017%2FS0265021503000322&rft_id=info%3Apmid%2F12650488&rft_id=info%3Apmid%2F12650488&rft.externalDocID=12650488 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0265-0215&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0265-0215&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0265-0215&client=summon |